← Back to Patent Explorer
US5908623A Expired / Lapsed US ⏱️ 0.0 years remaining

Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Assignee: Neurotech USA Inc
•
Filing: 1995-05-25
•
Granted: 1999-06-01
•
Expires: 2015-05-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal. In addition, this invention provides a general means for maintaining, for extended periods of time, the in vivo expression of transgenes.

Inventors

  • 👤 Edward E. Baetge
  • 👤 Joseph P. Hammang
  • 👤 Frank T. Gentile
  • 👤 Mark D. Lindner
  • 👤 Shelley R. Winn
  • 👤 Dwaine F. Emerich

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 19:59
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0092; A61K48/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/0085; C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/48; C07K14/665; C07K14/70; C12; C12N; C12N15/00; C12N15/09; C12N15/87; A61K38/00

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 99 words
A method for delivering a neurotrophic factor to the striatum of a mammalian host, the method comprising implanting at least one biocompatible capsule into the striatum of the host, each capsule comprising (a) a core comprising living mammalian cells secreting said neurotrophic factor, the cells having been transfected with a recombinant DNA molecule comprising a DNA sequence encoding said neutrotrophic factor operably linked to a promoter and wherein said cells stably express said neurotrophic factor; and (b) a biocompatible jacket surrounding the core, the jacket comprising a permselective membrane permitting passage of the neurotrophic factor thereacross into the host.
Claim 2
Independent Claim 99 words
A method for delivering a neurotrophic factor to the striatum of a mammalian host, the method comprising implanting at least one biocompatible capsule into the striatum of the host, each capsule comprising (a) a core comprising living mammalian cells secreting said neurotrophic factor, the cells having been transfected with a recombinant DNA molecule comprising a DNA sequence encoding said neutrotrophic factor operably linked to a promoter and wherein said cells stably express said neurotrophic factor; and (b) a biocompatible jacket surrounding the core, the jacket comprising a permselective membrane permitting passage of the neurotrophic factor thereacross into the host.
Claim 3
Dependent Claim 13 words
The method of claim 1 wherein the cells are xenogeneic to the host.
Claim 4
Dependent Claim 15 words
The method according to claim 1 wherein the neurotrophic factor is nerve growth factor (NGF).
Claim 5
Dependent Claim 12 words
The method according to claim 1 wherein the cells are BHK cells.
Claim 6
Dependent Claim 74 words
The method according to claim 1 wherein the neurotrophic factor is selected from the group consisting of nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), glial derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), neurotrophic factor-3 (NT-3), neurotrophic factor -4/5 (NT-4/5), epidermal growth factor (EGF), CDF/LIF, insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), platelet derived growth factor (PDGF), transforming growth factor (TGF), neurotensin, and Substance P.
Claim 7
Dependent Claim 39 words
The method of claim 1 wherein the jacket material is selected from the group consisting of polyacrylates, polyvinylidenes, polyvinylchloride copolymers, polyurethanes, polystyrenes, polyamides, cellulose acetates, cellulose nitrates, polysulfones, polyphosphazenes, polyacrilonitriles, poly (acrilonitrile/convinyl chloride), and derivatives, copolymers and mixtures thereof.
Claim 8
Dependent Claim 15 words
The method of claim 1 wherein the jacket is shaped to form a hollow fiber.
Claim 9
Dependent Claim 15 words
The method of claim 1 wherein the jacket is shaped to form a flat sheet.
Claim 10
Dependent Claim 19 words
The method of claim 1 wherein between one and six capsules are implanted in the straiatum of the host.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2002-05-31 2002-11-30 2003-06-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2006-05-31 2006-11-30 2007-06-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2010-05-31 2010-11-30 2011-06-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag